SHYNDEC(SH:600420)2025-01-19 08:20Financial Performance - The company expects a net profit attributable to shareholders of between 1.054 billion and 1.184 billion yuan for 2024, representing a year-on-year growth of 52.31% to 71.10%[3] - The net profit for 2023 was 691.88 million yuan, with a basic earnings per share of 0.5433 yuan[5] - The projected net profit excluding non-recurring gains and losses for 2024 is estimated to be between 1.012 billion and 1.142 billion yuan, reflecting a growth of 48.17% to 67.20% compared to the previous year[4] Factors Influencing Profit - The increase in profit is attributed to higher sales of penicillin and macrolide raw materials, along with improvements in gross margin due to process innovation and strategic collaboration[6] - The company has adjusted its marketing model and strengthened cost control, resulting in a significant decrease in the sales expense ratio[7] Performance Forecast - The performance forecast is based on preliminary calculations and has not been audited by an accounting firm[4] - The company does not foresee any major uncertainties that could affect the accuracy of the performance forecast[8] Industry Risks - The pharmaceutical industry is subject to cyclical fluctuations and may be impacted by policy changes and end-user demand, which could pose risks to future operations[8]